Coronary reserve in spontaneously hypertensive rats: the effect of blood pressure, hypertrophy and longterm vasodilator therapy

  • M. Klepzig
  • B. E. Strauer


Coronary reserve in man is reduced in concentric hypertensive hypertrophy. In 65-week-old spontaneously hypertensive rats (SHR) we found similar changes; in perfusion studies on isolated hearts the vasodilating capacity was restricted in comparison to Wistar Kyoto rats (WKY). Minimal coronary vascular resistance was 0.12 mm Hg · min · 100 g/ml versus 0.05 units in WKY (p < 0.0001). 60 weeks of antihy-pertensive therapy with hydralazine reduced coronary vascular resistance to 0.07 units (p< 0.0001). Under this treatment, blood pressure and heart weight/body weight ratios were also significantly reduced. Metoprolol, even when applied in high doses, reduced coronary vascular resistance only to 0.09 units (p< 0.0001); despite a modest reduction in blood pressure, the degree of myocardial hypertrophy remained constant. It may be concluded that an increase in coronary vascular resistance in SHR can be prevented by antihypertensive treatment with hydralazine; metoprolol treatment is less effective.

Key words

coronary reserve coronary resistance SHR — long-term antihypertensive therapy hydralazine metoprolol essential hypertension cardiac hypertrophy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ablad, B.: Hemodynamic effects of hydralazine. Arch. Pharmacol. Toxicol. (Suppl.) 20, 5–53 (1963).Google Scholar
  2. 2.
    Boström, S. L., J. Fryklund: Protein synthesis and composition of cardiac and vascular tissue in spontaneously hypertensive rats and the effects of beta-adrenergic antagonist treatment. Clinical science 57, 39–41 (1979).Google Scholar
  3. 3.
    Henrich, H., R. Hertel, R. Assmann: Structural differences in the mesentery microcirculation between normotensive and spontaneously hypertensive rats. Pflügers Arch. 375, 153–159 (1978).PubMedCrossRefGoogle Scholar
  4. 4.
    Kment, A., M. Klepzig, U. Bull, B. E. Strauer: Koronare Hämodynamik und myokardialer Sauerstoffverbrauch unter Dihydralazininfusion. Verh. dtsch. Ges. inn. Med. 86, 633–636 (1980).Google Scholar
  5. 5.
    Koch-Weser, J.: Hydralazine. N. Engl. J. Med. 295, 320–323 (1976).PubMedCrossRefGoogle Scholar
  6. 6.
    Marcus, M., M. Müller, C. L. Eastham: Effect of short-term ventricular hypertrophy on coronary circulation. Amer. J. Physiol. 241, H358–362 (1981).Google Scholar
  7. 7.
    Neely, J. R., H. liebermeiser, E. J. Battersby, H. E. Morgan: Effect of pressure development on oxygen consumption by isolated rat heart. Amer. J. Physiol. 212(4), 804–814 (1967).PubMedGoogle Scholar
  8. 8.
    Pegram, B., S. Ishise, E. D. Frohlich: Effect of methyldopa, clonidine and hydralazine on cardiac mass and hemodynamics in WKY and SHR. Cardiovasc. Res. 16, 40–46 (1982).PubMedCrossRefGoogle Scholar
  9. 9.
    Pfeffer, M., J. Pfeffer, K. Weiss, E. Frohlich: Development of hypertension and cardiac hypertrophy during prolonged beta blockade. Amer. J. Physiol. 232(6), H639-H644 (1977).Google Scholar
  10. 10.
    Pfeffer, J., M. Pfeffer, P. Fletcher, M. Fishbein, E. Braunwald: Favorable effects of therapy on cardiac performance in SHU. Amer. J. Physiol. 242, H776–H784 (1982).PubMedGoogle Scholar
  11. 11.
    Pfeffer, J., M. Pfeffer, E. Frohlich: Validity of an indirect tail cuff method for determining systolic arterial pressure in unanesthesized normotensive and spontaneously hypertensive rats. J. Lab. Clin. Med. 957–961 (1971).Google Scholar
  12. 12.
    Sen, S., F. M. Bumpus: Collagen synthesis in development and reversal of cardiac hypertrophy in SHR. Amer. J. Cardiol. 44, 954–958 (1979).PubMedCrossRefGoogle Scholar
  13. 13.
    Sivertson, R.: The hemodynamic importance of structural vascular changes in essential hypertension. Acta Physiol. Scand., Suppl. 343, 1–56 (1970).Google Scholar
  14. 14.
    Strauer, B. E.: Hypertensive heart disease. Springer (Berlin-Heidelberg-New York 1980).CrossRefGoogle Scholar
  15. 15.
    Strauer, B. E.: Koronare Mikrozirkulationsstörungen. Klin. Wschr. 59, 1125–1137 (1981).PubMedCrossRefGoogle Scholar
  16. 16.
    Wangler, R. D., K. Peters, M. Marcus, R. Tomanek: Effect of duration of arterial hypertension and cardiac hypertrophy on coronary vasodilatator reserve. Circulat. Res. 51, 10–18 (1982).PubMedGoogle Scholar
  17. 17.
    Wearn, J. T.: Alterations in heart accompanying growth and hypertrophy. Bull. Johns Hopk. Hosp. 68, 363–374 (1941).Google Scholar
  18. 18.
    Weiss, L.: Aspects of the relation between functional and structural cardiovascular factors in primary hypertension. Acta Physiol. Scand., Suppl. 409 (1974).Google Scholar
  19. 19.
    Weiss, L., Y. Lundgren: Left ventricular hypertrophy and its reversibility in young spontaneously hypertensive rats. Cardiovasc. Res. 12, 635–638 (1978).PubMedCrossRefGoogle Scholar
  20. 20.
    Yamori, Y., et al.: Cardiac hypertrophy in early hypertension. Amer. J. Cardiol. 44, 964–969 (1979).PubMedCrossRefGoogle Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag, GmbH & Co. KG, Darmstadt 1983

Authors and Affiliations

  • M. Klepzig
    • 1
  • B. E. Strauer
    • 1
  1. 1.Medizinische Klinik IKlinikum GroßhadernMünchen 70Germany

Personalised recommendations